CompletedPhase 2NCT00004163
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Marshall R. Posner, MDDana-Farber Cancer Institute
- Intervention
- Trastuzumab(drug)
- Enrollment
- 14 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2001
Study locations (10)
- Yale-New Haven Hospital, New Haven, Connecticut, United States
- Hematology/Oncology Associates, Port Saint Lucie, Florida, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Cape Cod Health Care, Hyannis, Massachusetts, United States
- Nantucket Cottage Hospital, Nantucket, Massachusetts, United States
- Washington University Barnard Cancer Center, St Louis, Missouri, United States
- Lourdes Regional Cancer Center, Binghamton, New York, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI) · Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00004163 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →